Ramadan fasting linked to favorable metabolic changes and reduced chronic disease risk

Ramadan fasting significantly reduces the risk of lung, colorectal, and breast cancers, showcasing beneficial metabolic changes through a comprehensive metabolomics investigation.

HOPO Therapeutics wins up to $226M BARDA contract for heavy metal poisoning research

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 29, 2024

SPT Labtech and Olink Announce New Automated Solution to Accelerate Research with Olink Next Generation Proteomics Technology

June 25, 2024

AstraZeneca reports positive Phase III results for Imfinzi in small cell lung cancer – Pharmaceutical Technology

Share this article Imfinzi is approved in the US, EU, Japan, China, and other countries for the treatment of extensive-stage SCLC (ES-SCLC) based on results

April 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.